Santiago Diaz Gonzalez
Neurology · Mobile, ALNPI 1619545993
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for neurology clinicians in AL, where the typical reported total is $2,219.
Across 83 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$254
- AstraZeneca$225
- Novartis$216
- UCB, Inc.$196
- Jazz Pharmaceuticals Inc.$181
- AbbVie$147
- plus $838 from 19 others
What the payments were for
- Food & beverage$2,057100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 8 | $254 |
| AstraZeneca | 9 | $225 |
| Novartis | 9 | $216 |
| UCB, Inc. | 8 | $196 |
| Jazz Pharmaceuticals Inc. | 4 | $181 |
| AbbVie | 8 | $147 |
| Bristol Myers Squibb | 1 | $100 |
| Amgen | 5 | $84 |
| Acadia Pharmaceuticals Inc | 3 | $74 |
| Merz Pharmaceuticals, LLC | 2 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Tanabe Pharma America, Inc. | 4 | $62 |
| Genentech USA, Inc. | 2 | $48 |
| Eisai Inc. | 2 | $44 |
| Neurelis, Inc. | 2 | $39 |
| EMD Serono, Inc. | 2 | $38 |
| Biogen | 2 | $34 |
| Acorda Therapeutics, Inc | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Catalyst Pharmaceuticals, Inc. | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Sanofi | 1 | $20 |
| Argenx US, Inc. | 1 | $19 |
| Grifols USA, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epidiolex$119
How this compares
$2,057 in reported general payments places this provider in the 45th percentile of 255 neurology providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Topiramate | 11 | $315 |
Paid to pharmacies, not to this prescriber.
Other neurology in Mobile
- Daniel DeesMobile$799K
- Hayden LongMobile$386K
- Charles MarkleMobile$212K
- William KilgoMobile$200K
- Bassam BassamMobile$197K
- Dean NaritokuMobile$160K
- Steve CordinaMobile$69K
- Thomas FosterMobile$51K
- Laura MintoMobile$33K
- Andrew ManleyMobile$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.